skip to main content

United Therapeutics Corporation to Announce Fourth Quarter and Annual 2009 Financial Results Before Market Open on Tuesday, February 16, 2010

SILVER SPRING, Md., Feb. 9 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its fourth quarter and annual 2009 financial results before market open on Tuesday, February 16, 2010.

United Therapeutics will host a half-hour teleconference on Tuesday, February 16, 2010, at 9:00 a.m. Eastern Time.  The teleconference is accessible by dialing 1-888-695-0608, with international callers dialing 1-719-325-2204.  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-888-203-1112, with international callers dialing 1-719-457-0820, and using conference code: 5260604.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.  [uthr-g]

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

SOURCE United Therapeutics Corporation

Recent Press Releases

The long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated patients with pulmonary arterial hypertension (PAH) met its primary endpoint and important secondary endpoints with...
SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors appointed Victor Dzau...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held...
LungFX™ is the first device approved for centralized ex vivo lung perfusion for donor organs not otherwise used for transplant, an important step in advancing United Therapeutics’ platformsSILVER SPRING, Md. &...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond,Chief Financial Officer and Treasurer, will provide a company...